Atabak Mokari's most recent trade in Corcept Therapeutics Inc was a trade of 28,460 Common Stock done at an average price of $87.9 . Disclosure was reported to the exchange on July 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 87.89 per share. | 15 Jul 2026 | 28,460 | 19,751 (0%) | 0% | 87.9 | 2,501,244 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.06 per share. | 15 Jul 2026 | 24,167 | 56,130 (0%) | 0% | 23.1 | 557,291 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2026 | 24,167 | 175,833 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.26 per share. | 15 Jul 2026 | 15,833 | 31,963 (0%) | 0% | 19.3 | 304,944 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2026 | 15,833 | 4,167 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 86.78 per share. | 15 Jul 2026 | 7,919 | 48,211 (0%) | 0% | 86.8 | 687,179 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 88.30 per share. | 15 Jul 2026 | 3,520 | 16,231 (0%) | 0% | 88.3 | 310,822 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 89.43 per share. | 15 Jul 2026 | 101 | 16,130 (0%) | 0% | 89.4 | 9,032 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.26 per share. | 15 Jun 2026 | 40,000 | 56,130 (0%) | 0% | 19.3 | 770,400 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 40,000 | 20,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 81.81 per share. | 15 Jun 2026 | 19,483 | 16,132 (0%) | 0% | 81.8 | 1,593,889 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 80.94 per share. | 15 Jun 2026 | 11,081 | 35,615 (0%) | 0% | 80.9 | 896,923 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 80.02 per share. | 15 Jun 2026 | 9,434 | 46,696 (0%) | 0% | 80.0 | 754,924 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 82.50 per share. | 15 Jun 2026 | 2 | 16,130 (0%) | 0% | 82.5 | 165 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 40,000 | 60,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 01 Jun 2026 | 40,000 | 15,257 (0%) | 0% | 70.0 | 2,800,004 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.26 per share. | 01 Jun 2026 | 40,000 | 55,257 (0%) | 0% | 19.3 | 770,400 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2026 | 634 | 16,525 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 70.44 per share. | 01 Jun 2026 | 634 | 15,891 (0%) | 0% | 70.4 | 44,659 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.44 per share. | 01 Jun 2026 | 395 | 16,130 (0%) | 0% | 70.4 | 27,824 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 397 | 14,956 (0%) | 0% | 36.0 | 14,280 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 397 | 15,353 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.97 per share. | 02 Mar 2026 | 96 | 15,257 (0%) | 0% | 36.0 | 3,453 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2026 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 178 | 14,677 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 178 | 14,499 (0%) | 0% | 79.8 | 14,201 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.78 per share. | 01 Dec 2025 | 118 | 14,559 (0%) | 0% | 79.8 | 9,414 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 71.38 per share. | 02 Sep 2025 | 200 | 14,265 (0%) | 0% | 71.4 | 14,276 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2025 | 200 | 14,465 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 71.38 per share. | 02 Sep 2025 | 144 | 14,321 (0%) | 0% | 71.4 | 10,279 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2025 | 775 | 14,584 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 71.68 per share. | 02 Jun 2025 | 775 | 13,809 (0%) | 0% | 71.7 | 55,552 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 71.68 per share. | 02 Jun 2025 | 519 | 14,065 (0%) | 0% | 71.7 | 37,202 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 140,000 | 140,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 232 | 13,034 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 59.07 per share. | 28 Feb 2025 | 232 | 12,802 (0%) | 0% | 59.1 | 13,704 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.58 per share. | 28 Feb 2025 | 228 | 12,570 (0%) | 0% | 60.6 | 13,812 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2024 | 231 | 12,798 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 59.21 per share. | 02 Dec 2024 | 231 | 12,567 (0%) | 0% | 59.2 | 13,678 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.68 per share. | 02 Dec 2024 | 182 | 12,336 (0%) | 0% | 57.7 | 10,498 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 400 | 12,518 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 34.26 per share. | 03 Sep 2024 | 400 | 12,118 (0%) | 0% | 34.3 | 13,704 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.30 per share. | 03 Sep 2024 | 143 | 11,718 (0%) | 0% | 35.3 | 5,048 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 1,448 | 11,861 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 31.30 per share. | 03 Jun 2024 | 1,448 | 10,413 (0%) | 0% | 31.3 | 45,322 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.17 per share. | 03 Jun 2024 | 571 | 8,965 (0%) | 0% | 30.2 | 17,227 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 24.06 per share. | 01 Mar 2024 | 554 | 8,982 (0%) | 0% | 24.1 | 13,329 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 554 | 9,536 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.06 per share. | 01 Mar 2024 | 517 | 8,428 (0%) | 0% | 24.1 | 12,439 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 200,000 | 200,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 508 | 8,945 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 25.97 per share. | 01 Dec 2023 | 508 | 8,437 (0%) | 0% | 26.0 | 13,193 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 1,651 | 7,408 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 22.97 per share. | 01 Jun 2023 | 1,651 | 5,757 (0%) | 0% | 23.0 | 37,923 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 19.86 per share. | 01 Mar 2023 | 1,260 | 2,846 (0%) | 0% | 19.9 | 25,024 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 1,260 | 4,106 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 793 | 1,586 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 25.98 per share. | 01 Sep 2022 | 793 | 793 (0%) | 0% | 26.0 | 20,602 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2022 | 200,000 | 200,000 | - | - | Stock option (right to buy) |